Clinical trial · Interventional
Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
Evaluating the Effect of ADRB2 Blockers on PKA/BAD/CREB Signaling in Patients Undergoing Prostatectomy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): PIs not interested in continuing with the trial.
Summary
Brief summary (as posted)
This randomized pilot clinical trial studies how well propranolol hydrochloride works in treating patients with prostate cancer who are undergoing surgery. When stressed, the body makes a molecule that may prevent tumor cells from dying, and propranolol hydrochloride may affect the signals in cells that cause tumor cells survival and death.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Carcinoma | Prostate Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Laboratory Biomarker Analysis | Other | — | UNRESOLVED |
| Propranolol Hydrochloride | Drug | — | UNRESOLVED |
| Questionnaire Administration | Other | — | UNRESOLVED |
| Survey Administration | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Group I (propranolol hydrochloride)
- description
- Patients receive propranolol hydrochloride PO 2 hours prior to standard of care prostatectomy.
- interventionNames
- Other: Laboratory Biomarker Analysis
- Drug: Propranolol Hydrochloride
- Other: Questionnaire Administration
- Other: Survey Administration
- type
- ACTIVE_COMPARATOR
- label
- Group II (no treatment)
- description
- Patients receive no treatment prior to standard of care prostatectomy.
- interventionNames
- Other: Laboratory Biomarker Analysis
- Other: Questionnaire Administration
- Other: Survey Administration
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of prostate cancer undergoing prostatectomy * Individuals able to understand and willing to sign an Institutional Review Board (IRB)-approved informed consent document Exclusion Criteria: * Men taking propranolol on a daily for any reason are excluded * Men with baseline systolic blood pressure (SBP) \< 110 or heart rate (HR) \< 60 * Men unable to swallow pills * History of current or past medical or psychiatric illness that would make participation difficult or not feasible at the discretion of the principal investigator or co-investigators
References
Publications (0)
Data not yet available